Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Fiztasovimab (NPC-21; EV2038), a fully human IgG1λ monoclonal antibody (mAb), targets human cytomegalovirus (hCMV). It exerts its neutralizing activity through binding to the antigenic domain 1 of glycoprotein B on the hCMV envelope, effectively inhibiting cell-to-cell transmission of hCMV [1].
説明 | Fiztasovimab (NPC-21; EV2038), a fully human IgG1λ monoclonal antibody (mAb), targets human cytomegalovirus (hCMV). It exerts its neutralizing activity through binding to the antigenic domain 1 of glycoprotein B on the hCMV envelope, effectively inhibiting cell-to-cell transmission of hCMV [1]. |
分子量 | N/A |
CAS No. | 2467411-25-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Fiztasovimab 2467411-25-0 Inhibitor inhibitor inhibit